Vendor Intelligence Report: Zhang TY

Published 13 Jun 2026. 19-page investigative report on who is behind Zhang TY: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Zhang TY has 3 pass / 1 fail — overall pass rate 75%. The record is small and product-specific rather than catalog-wide. Retatrutide is the comparative bright spot so far, while Tesamorelin is the current poor-choice signal. The report also shows why methodology sensitivity matters more when a vendor has only four tests.

The public sales identity does not read like a documented manufacturer. Finnrick lists Zhang TY in China with Instagram @zhang006211 as the directory contact, while the observed Zhang Peptides storefront presents U.S. contact details and an Ohio address that records tie to a different peptide company. The same footprint moves through Zhang TY, Zhang Hk, and Soren Zhang aliases, with a small Instagram snippet, Telegram handles, a TikTok result, and no verified corporate entity in the supplied record.

The storefront evidence is unusually concrete: a generic WooCommerce medical template, placeholder About-page text, and product images with Google Gemini-generated filenames rather than real vial photos or lot-specific analytical documents. Search results are also polluted by doorway pages using Zhang TY peptide keywords and sending traffic toward peptide.mom; the report treats attribution cautiously, but the channel-verification risk is real.

For buyers, the actionable read is narrow. Zhang TY may be a defensible Retatrutide candidate only with fresh, batch-specific third-party confirmation. It is a poor current choice for Tesamorelin, and untested listings such as BPC-157 or Cagrilintide should not inherit Retatrutide’s pass pattern.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for both tested products
  • Channel map of @zhang006211, @soren.zhangpeptides5, Telegram handles, and the Zhang Hk / Soren Zhang aliases
  • Address analysis comparing the storefront’s Ohio claim to Ohio Peptide LLC records
  • Media-library evidence of Gemini-generated logo and product images, including Tesamorelin, BPC-157, and Cagrilintide
  • Doorway-domain analysis covering peptideai.xyz, nnxfou.com, fcapuw.info, bvgjbb.com, and peptide.mom
  • Reputation and promotion sweep, including the Reddit thread, TikTok dead ends, and X/web coupon scan

Risk assessment

  • False US presence and misappropriated-address risk — high: Zhang Peptides lists 195 W Olentangy St Suite O, Powell, OH 43065, but supplied records tie that address to Ohio Peptide LLC while Finnrick lists Zhang TY in China.
  • Unverifiable storefront and AI-generated product-imagery risk — high: The storefront uses Google Gemini-generated product images and template filler, with no real product photos, verifiable COAs, lab images, or anti-counterfeit process observed.
  • Tesamorelin quality risk — high: Tesamorelin is product-specific: Finnrick has 1 test, 0 passes, 1 fail, and a 42.46% rating, making Zhang TY a poor current choice for this peptide.
  • Brand-confusion and unofficial-doorway risk — medium: Doorway domains using Zhang TY peptide keywords redirect toward peptide.mom, and Zhang TY does not provide strong canonical-channel, reseller, COA, or anti-counterfeit verification signals.
  • Weak identity and reputation-corroboration risk — medium: The operation appears across Zhang TY, Zhang Hk, and Soren Zhang identities with small social accounts, no verified corporate entity in the supplied record, and little organic community trust.